Tildacerfont as antidepressant medication: a phase II randomized controlled trial (TAMARIND)

Neuroscience Applied 2026 Open access

Read full text
Authors: A. Glas, H. Eriksson, C. zu Eulenburg, B. Mueller-Myhsok, E. Papanastasiou
DOI: 10.1016/j.nsa.2025.105675
Cited by: 0

Fields of Study & Subjects

Treatment of Major Depression Medication Adherence and Compliance Pharmacological Receptor Mechanisms and Effects

Publication details

Journal / source
Neuroscience Applied
Volume
5
Pages
105675–105675
Publication date
1 January 2026
Language
EN